Medtech

Fresenius Medical Care launches "Augmented Reality" for training on Kidney Replacement Therapy device

Retrieved on: 
Tuesday, March 19, 2024
Ready4, Fresenius Medical Care, Learning, Safety, Kidney, Augmented reality, Education, Knowledge, Hospital, Emergency medicine, Augment, Intensive care medicine, Dialysis, FME, BAD, ICU, Nursing, Health, Medtech

The glasses stream visual and acoustic recordings as users interact with the dialysis machine, providing professionals with an immersive learning experience.

Key Points: 
  • The glasses stream visual and acoustic recordings as users interact with the dialysis machine, providing professionals with an immersive learning experience.
  • Our innovative solution is designed to ensure that nursing staff, particularly those in Intensive Care Units, are equipped with the knowledge needed to provide high-quality and exceptional patient care," says Dr. Katarzyna Mazur-Hofsäß, member of the Management Board of Fresenius Medical Care AG and responsible for Care Enablement, Fresenius Medical Care's MedTech segment.
  • The AR glasses provide access to the Augmented Reality learning program Ready4 multiFiltratePRO AR, which Fresenius Medical Care presented today at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels.
  • Ready4 multiFiltratePRO AR has been specifically developed for use with the multiFiltratePRO, Fresenius Medical Care's Continuous Kidney Replacement Therapy system.

IVD Survival Guide: Navigating Uncertainty in the US and European IVD Regulatory Landscape, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, March 18, 2024
Research, IVD, Medtech, 2005 in television, Regulatory affairs, FDA, IVDR, Medical device

TORONTO, March 18, 2024 /PRNewswire-PRWeb/ -- In vitro diagnostic (IVD) testing has become a cornerstone of modern medicine, with an estimated 70 percent of medical decisions made based on laboratory test results. Given the vital role IVDs play in guiding care, regulatory agencies frequently review approval requirements, and the regulatory frameworks governing these devices are constantly evolving.

Key Points: 
  • In this free webinar, gain insights into how regulatory guidance can help in vitro diagnostic (IVD) developers proactively navigate uncertainty and mitigate potential financial, compliance and operational risks.
  • Attendees will learn about the FDA's proposed rule to regulate laboratory-developed tests (LDTs) as IVDs and the FDA's reclassification for high-risk IVDs.
  • The featured speakers will discuss key changes introduced by the EU In Vitro Diagnostics Regulation (IVDR).
  • Register for this webinar today to gain insights into how regulatory guidance can help IVD developers proactively navigate uncertainty and mitigate potential financial, compliance and operational risks.

Armonica Technologies announces Todd Dickinson joins Board of Directors

Retrieved on: 
Wednesday, March 13, 2024
SAN, Medicine, DNA, Medtech, Doctor of Philosophy, Fine chemical

SAN DIEGO, March 13, 2024 /PRNewswire/ -- Armonica Technologies, Inc., a pioneer in sample-prep free direct optical DNA sequencing, today announced the appointment of life science leader Todd Dickinson to the Board of Directors.

Key Points: 
  • SAN DIEGO, March 13, 2024 /PRNewswire/ -- Armonica Technologies, Inc., a pioneer in sample-prep free direct optical DNA sequencing, today announced the appointment of life science leader Todd Dickinson to the Board of Directors.
  • Armonica Technologies is a MedTech company focused on developing its advanced long-read sequencing platform for precision medicine applications.
  • "We're extremely excited to welcome Todd to our board.
  • His combination of technical and commercial expertise is a fantastic fit for Armonica, and will add value to the company in every aspect of our development" said Victor Esch, PhD, CEO of Armonica Technologies.

Azenta to Participate in the Virtual KeyBanc Life Sciences & MedTech Investor Forum

Retrieved on: 
Tuesday, March 12, 2024
Webcast, Medtech

BURLINGTON, Mass., March 12, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in Virtual KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, which includes a presentation beginning at 12:45 pm ET.

Key Points: 
  • BURLINGTON, Mass., March 12, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in Virtual KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, which includes a presentation beginning at 12:45 pm ET.
  • The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events .
  • A replay of the webcast will be available following the event.

Medical technology back on track

Retrieved on: 
Wednesday, March 13, 2024
Hospital, CNMV, Growth, Annual report, TEL, Cigna, House, Health, Acceleration, Intuitive Surgical, Medtech, Post office box, SICAV, Judgement, Humana, HCA Healthcare, Congress, Environment, Lux, South, Harmony Row, Conference, AG, Medtronic, Capital, Investment, Research, Prospectus, Intelligence, SIX Swiss Exchange, CHF, Intuition, Risk, Medicare, Grand Canal Dock, Pharmaceutical industry

The broad healthcare sector and the medical technology sector, buoyed by resurgent investor interest, delivered even better returns.

Key Points: 
  • The broad healthcare sector and the medical technology sector, buoyed by resurgent investor interest, delivered even better returns.
  • “We also anticipate a big boost in growth from the increasing use of artificial intelligence in the medical technology and healthcare services industries,” Stefan Blum adds.
  • These were generally characterized by strong growth momentum in surgical procedures and an optimistic outlook for the 2024 fiscal year,” Marcel Fritsch comments.
  • Elevance, which is focused on employer-sponsored health insurance plans, reported better-than-expected profits thanks to a drop in medical costs and an increase in management’s earnings guidance for 2024.

Affluent Medical : Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve.

Retrieved on: 
Wednesday, March 13, 2024
Mitral regurgitation, Ticker, Aix-en-Provence, Doctor of Philosophy, MD, Overalls, Physiology, Hospital, Minerva, Risk, Tricuspid valve, Mayo Clinic, Clinical professor, Death, American College, Medtech, Mitral valve, Patient, Interventional cardiology

Affluent Medical : Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve.

Key Points: 
  • Affluent Medical : Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve.
  • The article summarizes the procedure and the follow up at 6 months, which showed continued good prosthetic performance.
  • Examination through a transesophageal echocardiogram revealed excellent valve performance, with neither mitral regurgitation nor paravalvular leak.
  • Mitral valve regurgitation is a serious and potentially fatal disease affecting 2% of the world's population, or approximately 160 million people.

Affluent Medical announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence.

Retrieved on: 
Wednesday, March 13, 2024
Taboo, Anxiety, Woman, Mental health, Ticker, Doctor of Philosophy, EAU, Neurostimulation, Urethra, MD, Pathology, Nursing, Quality of life, Female, Prostate, Urinary incontinence, Hope, Life, European, Health, Incontinence, Medtech, Patient, Disorder, Child, Male, European Association of Urology, Trial of the century, Ageing, Animation, Wound healing, Medical device

Affluent Medical announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence.

Key Points: 
  • Affluent Medical announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence.
  • This first implantation of the artificial urinary sphincter Artus was successfully performed by Prof. Roman Zachoval, MD, PhD, head of the Department of Urology at Thomayer University Hospital in Prague, Czech Republic, on a 68-year-old male with severe urinary incontinence.
  • “Artus is easy to prepare and implant due to its innovative design compared to the previous generation of urinary sphincters.
  • Artus is an implantable artificial urinary sphincter developed for the treatment of moderate to severe urinary incontinence in both men and women.

Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Retrieved on: 
Friday, March 8, 2024
XGN, Medtech

CARLSBAD, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, which takes place virtually March 19-20, 2024.

Key Points: 
  • CARLSBAD, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, which takes place virtually March 19-20, 2024.
  • John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Exagen’s Chief Financial Officer, will participate in one-on-one meetings with investors and a fireside chat on Wednesday, March 20, at 1:30 PM ET.

Blade Air Mobility to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, March 6, 2024
Management, Medtech, Conference

NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Blade Air Mobility, Inc. (Nasdaq: BLDE, “Blade” or the “Company”), a technology-powered air mobility platform, today announced that Management will participate in the following investor conferences:

Key Points: 
  • NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Blade Air Mobility, Inc. (Nasdaq: BLDE, “Blade” or the “Company”), a technology-powered air mobility platform, today announced that Management will participate in the following investor conferences:
    2024 J.P. Morgan Industrials Conference – Presentation and fireside chat with Will Heyburn, Chief Financial Officer, on Tuesday, March 12, 2024 at 3:35pm ET.
  • A webcast of the event will be available at the link here .
  • Oppenheimer 34th Annual Healthcare MedTech & Services Conference – Fireside chat with Seth Bacon, Chief Executive Officer of Blade Medical, and Scott Wunsch, Chief Operating Officer of Blade Medical, on Wednesday, March 13, 2024 at 2:00pm ET.
  • A webcast of the event will be available at the link here .

Noah Medical Named a “Fierce 15” Company of 2023 by Fierce MedTech

Retrieved on: 
Wednesday, March 6, 2024
SAN, Fierce, Physician, Growth, Silicon, Fluoroscopy, Medtech, Patient, Lung cancer, Galaxy, Diagnosis, Noah, Medical device

SAN CARLOS, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Medical robotics innovator Noah Medical announced today that Fierce MedTech has named it one of 2023’s “Fierce 15” medical technology companies.

Key Points: 
  • SAN CARLOS, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Medical robotics innovator Noah Medical announced today that Fierce MedTech has named it one of 2023’s “Fierce 15” medical technology companies.
  • “Winning the Fierce 15 award is a shared triumph for both our exceptional team at Noah and the customers who’ve played an instrumental role in making Galaxy a leader in minimally invasive early lung cancer diagnosis,” said Noah Medical CEO Jian Zhang.
  • The Galaxy System was also recently recognized as a Medtech Breakthrough winner and named a finalist in the 2023 Fierce Innovation Awards: Life Sciences Edition.
  • “These companies exemplify the ability of the MedTech industry to turn cutting-edge ideas into meaningful outcomes and make them accessible on a large scale.”
    To learn more about Noah Medical and the Galaxy System, please visit noahmed.com .